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Objective
To elucidate the functional erection rate after prostate
stereotactic body radiotherapy (SBRT) and to develop a
comprehensive prognostic model of outcomes after treatment.
Patients and Methods
Between 2008 and 2013, 373 consecutive men with localized
prostate cancer were treated with SBRT at a single academic
institution as part of a prospective clinical trial or prospective
registry. Prospective longitudinal patient-reported health-
related quality of life (HRQoL) data was collected using the
Expanded Prostate Cancer Index Composite (EPIC)-26
instrument. Functional erections were strictly defined as ‘firm
enough for intercourse’ according to EPIC-26. Detailed
comorbidity data were also collected. Logistic regression
models were used to predict 24- and 60-month functional
erection rates. Observed erection rates after SBRT were
compared with those after other radiation therapies (external
beam radiation therapy [EBRT] and brachytherapy) using
prospectively validated models.
Results
The median (interquartile range) follow-up was 56 (37–73)
months and the response rate at 2 years was 84%. For those
with functional erections at baseline, 57% and 45% retained
function at 24 and 60 months, respectively. On multivariable
analysis for 24-month erectile function, significant variables
included higher baseline sexual HRQoL (adjusted odds ratio
[aOR] 1.55 per 10 points, 95% confidence interval [CI] 1.37–
1.74; P < 0.001) and older age (aOR 0.66 per 10 years, 95%
CI 0.43–1.00; P = 0.05). At 60 months, baseline HRQoL and
age remained associated with erectile function, along with
body mass index (aOR 0.45, 95% CI 0.26–0.78; P < 0.001).
The 24- and 60-month models had excellent discrimination
(c-index 0.81 and 0.84, respectively). Erection rates after
SBRT were not statistically different from model-predicted
rates after EBRT or brachytherapy for the whole cohort and
the cohort with baseline erectile function.
Conclusions
Intermediate- to long-term post-SBRT erectile function results
are promising and not significantly different from other
radiotherapy techniques. Clinicians can use our prognostic
model to counsel patients regarding expected erectile function
after SBRT.
Keywords
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Introduction
The Prostate Testing for Cancer and Treatment (ProtecT)
trial recently reported the outcomes of men with
predominantly low-risk prostate cancer randomized to one of
three upfront treatment strategies: nerve-sparing radical
prostatectomy (RP); conventionally fractionated external
beam radiation therapy (EBRT); or active surveillance [1].
Overall survival was similar in all groups, but ~50% of men
in the active surveillance arm eventually underwent definitive
treatment. For men who do undergo radical treatment, an
understanding of its impact on health-related quality of life
(HRQoL) is critically important to inform decision-making,
given the equivalent efficacy demonstrated for RP and EBRT
[1,2]. Among HRQoL domains, sexual function is most
commonly and significantly affected by radical therapy, and
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sexual function outcomes correlate closely with overall
treatment satisfaction [3–5].
Much has changed, however, in the 17 years since the first
patient was enrolled in ProtecT. Surgical techniques have
evolved [6], and radiotherapeutic advances have allowed the
advent of high-dose-per-fraction, image-guided, ultra-
hypofractionated treatment to the prostate, termed
stereotactic body radiotherapy (SBRT). Often delivered over
five treatments, SBRT is convenient and cost-effective relative
to conventional EBRT courses of 8–9 weeks [7,8], with a
promising overall toxicity profile [9–11] that is currently
being investigated in numerous randomized trials [12,13].
Concern remains, however, about the delayed effects of SBRT
given its high-dose per fraction and mechanism of cellular
injury [14]. There are few existing data on long-term
functional erection outcomes after SBRT, hindering the
clinical counselling of men considering this therapeutic
approach. Prognostic models of functional erections have
been developed after treatment with nerve-sparing RP,
conventional EBRT, and brachytherapy [15], but notably
absent are similar models after SBRT.
To better understand the impact of SBRT on erectile
function, in the present paper, we report the results of a large
prospective study using patient-reported outcomes, including
a detailed set of comorbidities believed to affect sexual health
to develop our models. Furthermore, we compared rates of
erectile function across treatment methods using validated
model-predicted rates for other radiation techniques
performed at centres of excellence.
Materials and Methods
Patients
Between January 2008 and November 2013, 373 patients with
localized biopsy-proven prostate adenocarcinoma were
consecutively treated with SBRT as per an institutional
protocol (NCT01766492) or on a prospective registry. Eligible
patients included those with cT1c–T2c disease, cN0 Gleason
scores 6–10, and PSA levels <50 ng/mL. Patients who had
previously undergone pelvic radiotherapy or prostate surgery
were excluded. Patients were staged according to National
Comprehensive Cancer Center (NCCN) guidelines; high-risk
patients were staged with the addition of a CT of the
abdomen and pelvis and a bone scan. Prostate MRI was
recommended and routinely used. All patients received
baseline PSA testing prior to initiation of any therapy.
All patients were required to have baseline patient-reported
HRQoL data, which consisted of the Expanded Prostate
Cancer Index Composite (EPIC)-26 [16]. Additional
prospective sexual health inventory data were collected,
including the International Index of Erectile Function short
version (IIEF-5, also known as the Sexual Health Inventory
for Men [SHIM]) [17].
Treatment
Image-guided prostate SBRT was delivered using Cyberknife
(Accuray, Sunnyvale, CA, USA). SBRT treatment planning
and delivery have been described previously [18].
Pretreatment CT and MRI registration were used for volume
delineation. CT included the prostate and the proximal
seminal vesicles. The planning target volume equalled the
clinical target volume expanded by 3 mm posteriorly and
5 mm in all other dimensions. Patients were treated with 35–
36.25 Gy in five fractions (SBRT). Radiation was delivered
every other day to a prescription isodose line of 75–80%, with
a target coverage goal of ≥95%. The penile bulb was
contoured with a dose–volume histogram goal of <25%
receiving 29.5 Gy. Individual erectile structures, such as
internal pudendal arteries, neurovascular bundles or nerve
plexus, were not specifically contoured or avoided. Image
guidance was applied using paired, orthogonal X-rays. Target
position was verified every 1–2 min, with a minimum of
three adequately separated, non-overlapping fiducials.
Beyond the 373 in the current cohort, 24 additional patients
were treated during the study period with neoadjuvant
androgen deprivation therapy (ADT), consisting of 3–
6 months of an LHRH agonist; however, only 4/24 patients
receiving ADT had baseline functional erections, limiting
meaningful analysis. These patients receiving ADT were
therefore not included in the present study.
Erectile Function Definition
As advocated by the National Cancer Institute Prostate
Cancer Working Group, we report patient-reported sexual
outcomes longitudinally [19]. The EPIC sexual function
domain is a composite score of 0 to 100, comprising five
questions related to sexual function and one question related
to sexual bother; higher values represent improved HRQoL.
‘Functional erection’ was the primary metric used in the
present study, and was strictly defined as the patient-reported
response of having erections ‘firm enough for intercourse’ in
the past 4 weeks, irrespective of use of sexual aids, on
question 9 of the EPIC-26, in accordance with the National
Institutes of Health definition of erectile function [20]. Given
that SHIM scores were also collected, we also compared
functional erections defined by SHIM ≥16 with those defined
by EPIC.
Covariables
Age and pretreatment EPIC sexual function domain HRQoL
scores were analysed as continuous variables or as a binary
variable when specified. Additional patient-related variables
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thought to be related to erectile function were analysed
including baseline sexual medications, partner status, body
mass index (BMI), diabetes, hypertension, coronary artery
disease, major depression, and pretreatment testosterone.
Tumour-related variables included PSA (ng/mL), T stage, and
Gleason score. Treatment-related variables included
prescribed SBRT dose < 36.25 or ≥36.25.
Treatment Method Comparisons
To compare rates of erectile function preservation after SBRT
with other radiation therapies (EBRT and brachytherapy), our
individual patient clinical characteristics were entered into
validated models that have been shown to predict 24-month
post-treatment erectile function for both EBRT and
brachytherapy [15]. These models were generated from the
Prostate Cancer Outcomes and Satisfaction with Treatment
Quality Assessment (PROSTQA) multicentre cohort, and
validated in a Cancer of the Prostate Strategic Urologic
Research Endeavor (CaPSURE) cohort.
Statistical Analysis
To explore differences in patients who were lost to follow-up
(Table S1), logistic regression was used to predict missing
data at 24 and 60 months based on a decline in sexual
HRQoL in the first 12 months and the second 12 months of
follow-up. Patients with decline in sexual function were more
likely to have data collection at 24 months, suggesting no
selection bias as a result of poor follow-up of those with
significant HRQoL declines. Furthermore, analyses of missing
patients at 60 months revealed no other associations with
sexual function decline; thus, missing data were assumed to
be missing at random and imputation was not performed.
Univariable logistic regression analysis (UVA) and
multivariable logistic regression analysis (MVA) were
performed to generate models of predictors of functional
erections over time. The primary endpoint was at 24 months,
consistent with a previous analysis of other radiation
techniques [15]. Additional models were generated to predict
function at 60 months. All patients were included in the
modelling, including those without baseline erectile function,
as 10–15% of patients who report no function at baseline
regain function at later time points. Odds ratios (ORs),
adjusted ORs (aORs), and 95% CIs are reported. For the
logistic regression model to predict functional erections, 95%
Wald CIs were calculated from the estimated covariance
matrix. C-indices were calculated to determine the
discriminatory performance of the model. Age was included
in all MVA models, given its known association with sexual
function. Variables with P < 0.1 on UVA, plus comorbidities
known to be associated with sexual function (diabetes,
hypertension, coronary artery disease and major depression),
were tested in the MVA model. Stepwise backward
elimination was used; two-sided P values of <0.05 were
considered statistically significant. Statistical analyses were
performed using SAS version 9.3.
Results
Baseline and Treatment Characteristics
The median (interquartile range [IQR]) follow-up was 56
(37–73) months. The median (IQR) age was 69 (64–73) years
and 124 (33%), 233 (63%), and 16 patients (4%) were
classified as low, intermediate and high risk according to the
NCCN criteria, respectively. Detailed pretreatment
comorbidities are shown in Table 1. Baseline EPIC sexual
function domain HRQoL was available for all 373 patients. A
total of 312 patients had EPIC follow-up assessment at
24 months (84% of eligible patients [Table 1]), and response
rates did not vary between those with or without baseline
erectile function.
Longitudinal Sexual HRQoL and Functional Erection
Outcomes
The median (IQR) baseline HRQoL score was 56 (29–82).
Baseline global sexual HRQoL was equally split between 182
patients (49%) with higher baseline function (HRQoL score
60–100) and 191 patients (50%) with poor function (HRQoL
score < 60 [Table S2]). At 24 and 60 months after SBRT,
107/312 (34%) and 44/170 (26%) reported functional
erections, respectively (Fig. 1A). A total of 184 men (49%)
had functional erections at baseline and 89/157 (57%) and
39/87 (45%) retained function at 24 and 60 months,
respectively (Fig. 1B). Figures 1C and D show the decline in
erectile function over time by age, with older patients (age
≥65 years) having a more continual decline of erectile
function over time compared with younger patients, who
appeared to reach a plateau.
Baseline SHIM scores were available for 372/373 patients
(99%); 182 (49%) had a baseline SHIM ≥16 which decreased
to 107/311 (34%) and 51/167 (30%) at 24 and 60 months
respectively. Using this SHIM definition, erectile function
rates were nearly identical to those estimated by EPIC
(Fig. S1).
Predictors of Functional Erections
On UVA, the following factors were associated with
decreased erectile function at 24 months: older age, lower
pretreatment sexual HRQoL, and T stage [all P ≤ 0.01];
Table 2). Older age and lower pretreatment sexual HRQoL
(both P < 0.001) remained associated with decreased function
at 60 months, in addition to elevated BMI (P = 0.005),
diabetes (P = 0.039) and hypertension (P = 0.025). On MVA,
higher baseline sexual HRQoL was associated with improved
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function erection rates both at 24 months (aOR 1.55 per 10-
point increase [95% CI 1.37–1.74]; P < 0.001) and 60 months
(aOR 1.54 per 10-point increase [95% CI 1.27–1.87]; P <
0.001). Older age was associated with decreased function at
both 24 and 60 months. At 60 months, BMI was the only
comorbidity independently associated with a significant
decline in functional erections on MVA (aOR 0.45 [95% CI
0.26–0.78]; P < 0.001).
Table 3 shows the results from our MVA model-predicted
functional erection rate at 24 months after SBRT (c-index
0.81 [95% CI 0.76–0.86]) and 60 months after SBRT (c-index
0.83 [95% CI 0.79–0.88]). The model predictions ranged from
<10% (95% CI 4–12) for a 70-year-old man with baseline
HRQoL of 25 to 80% (95% CI 68– 87) for a 60-year-old with
baseline HRQoL of 100. Similar ranges are seen at
60 months, with BMI further informing predicted rates. As
seen in Table 3, a decrease in BMI of 5 points increases the
predicted 5-year functional erection rates by 10–20 percentage
points.
Treatment Method Comparison
A total of 312 patients had follow-up at 24 months. Using
previous prospectively validated models of 24-month
functional erections after EBRT and brachytherapy [15],
model-predicted rates for this cohort of men were 37% (95%
CI 33–40) with EBRT and 32% (95% CI 28–35) with
brachytherapy. The rate of actual functional erections after
SBRT was 34% (95% CI 29–40), a rate not statistically
significantly different from that after EBRT (P = 0.31) or
brachytherapy (P = 0.30; Table 4). In patients with baseline
erectile function, a similar lack of difference among the
treatment methods was noted.
Discussion
Erectile dysfunction after treatment for localized prostate
cancer is a common side effect and a major patient concern
[3]. In a large cohort, broadly representative of those
diagnosed with prostate cancer, we report intermediate- and
long-term functional erection outcomes after high-dose-per-
fraction treatment with prostate SBRT. Questionnaire
response rates were robust over time (24 months: 84%), and
there was substantial follow-up of up to 60 months, with no
evidence of selection bias in those lost to follow-up. Among
those with baseline erectile function, 57% and 45% retained
erectile function at 24 and 60 months, respectively.
These results are consistent with several smaller previously
reported SBRT series using similar strict EPIC-based criteria.
For example, in a Stanford phase II trial of 32 patients
receiving prostate SBRT, 62% of patients reported erections
firm enough for intercourse at baseline, which declined to
29% at 50 months [21]. Others have obtained similar findings
using different patient-reported sexual outcome measures.
The HYPO-RT-PC non-inferiority trial randomized men to a
seven-fraction regimen of SBRT vs standard EBRT, and
Table 1 Characteristics of the study cohort.
Patient characteristics
Age, years
Median (IQR) 69 (64, 73)
BMI, kg/m2
Median (IQR) 28 (25, 31)
BMI, n (%)
<30 kg/m2 256 (69)
>30 kg/m2 111 (30)
>40 kg/m2 6 (2)
Partner status
Not married 94 (25)
Married 278 (75)
Diabetes
Absent 295 (79)
Present 77 (21)
Hypertension
Absent 112 (30)
Present 260 (70)
Coronary artery disease
Absent 307 (83)
Present 65 (17)
Major depression
Absent 343 (92)
Present 28 (8)
Pretreat testosterone
Median (IQR) 320 (234, 437)
Baseline sexual medications
No 223 (62)
Yes 139 (38)
Tumour and treatment characteristics, n (%)
T-stage
T1c–T2a 321 (86)
T2b–c 51 (14)
T3 1 (0)
Grade group (Gleason), n (%)
1 (6) 165 (44)
2 (3 + 4) 147 (39)
3 (4 + 3) 53 (14)
4 (4 + 4) 8 (2)
5 (9 or 10) 1 (0)
Pretreatment PSA level, ng/mL
Median (IQR) 6 (5, 9)
≤10 ng/mL 308 (83)
>10–20 ng/mL 58 (16)
>20 ng/mL 7 (2)
Risk group*
Low 124 (33)
Favourable intermediate risk 140 (38)
Unfavourable intermediate risk 93 (25)
High risk 16 (4)
SBRT dose
<36.25 132 (35)
≥36.25 241 (65)
*Risk group adapted from National Comprehensive Cancer Network and the
Zumsteg/Spratt risk classification. Low: T1–T2a, Gleason ≤ 6, PSA <10 ng/mL;
favourable intermediate: Gleason ≤ 6 with one intermediate risk factor OR Gleason 3
+ 4 as only factor; unfavourable intermediate: Gleason 4 + 3 OR multiple
intermediate risk factors; high risk: T3 OR Gleason 8–10 OR PSA >20 ng/mL.
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recently reported preliminary results in abstract form. Using
the Prostate Cancer Symptom Scale [22], 2-year ‘potency’ was
34% and unchanged compared with EBRT, similar to the
present results [13].
The present MVA of erectile function after SBRT identified
several patient-related factors associated with functional
erections. Better baseline HRQoL was strongly associated with
functional erections at 24 and 60 months after treatment,
consistent with findings with regard to EBRT and
brachytherapy [15,23]. Older patients were more likely to
experience decline in the rate of functional erections, similar
to the decline experienced in older patients without prostate
cancer [24,25], as well as those patients treated with RP and
brachytherapy [15]. At 60 months, increasing BMI was also
associated with a greater likelihood of functional erection
decline, similar to those treated with brachytherapy [15].
Interestingly, while our UVA identified diabetes and
hypertension as associated with declines in 60-month erectile
function, these comorbidities were no longer significant after
including age, baseline sexual function and BMI. Age, HRQoL
and BMI are key confounders to keep in mind in any
treatment method comparison, and they probably capture
several other underlying comorbid contributions to sexual
health, such as diabetes and hypertension.
Our sexual function outcomes after SBRT appear to be
similar to EBRT and brachytherapy based on validated
prediction models. These prediction models are advantageous
as they were generated from treatments at centres of
excellence, were externally validated, and allow patient-level
comparison of treatment methods. Some may point out,
fairly, that these models were based on patients treated with
older, three-dimensional conformal radiation treatment
techniques. Fortunately, recent efforts have provided
important insights regarding sexual quality-of-life outcomes
Timepoint 0 3 6 12 24 36 60
n 373 346 342 331 312 274 170
Timepoint 0 3 6 12 24 36 60
n 184 174 167 164 157 137 87
Timepoint 0 3 6 12 24 36 60
Age < 65 112 104 101 95 88 79 44
Age ≥ 65 261 242 241 236 224 195 126
N=
Timepoint 0 3 6 12 24 36 60
Age < 65 70 65 61 62 58 49 26
Age ≥ 65 114 109 106 102 99 88 61
100%
80%
60%
40%
20%
0%
0 3 6 12
Months
Overall Cohort
24 36 60
100%
80%
60%
40%
20%
0%
0 3 6 12
Months
Patients with Erectile Function Pretreatment
24 36 60
100%
80%
60%
40%
20%
0%
0 3 6 12
Months
Age Age < 65
≥ 65< 65
≥ 65
24 36 60
100%
80%
60%
40%
20%
0%
0 3 6 12
Months
24 36 60
A B
C D
Fig. 1 Unadjusted proportions of patients reporting functional erections at each follow-up for the whole cohort (A), those with baseline erectile function
(B), the whole cohort dichotomized by age 65 years (C), and those with baseline erectile function dichotomized by age 65 years (D).
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with modern intensity-modulated radiotherapy (IMRT)
[26,27]. Barocas et al. [27] used the same EPIC-based quality-
of-life instrument reported in the present study, and
importantly, >80% were treated with IMRT. Age and baseline
sexual HRQoL was similar between the EBRT group in the
Barocas study and the present study: mean age of 68 vs
69 years and mean baseline sexual HRQoL of 52 vs 55,
respectively. The percentage of men with baseline erectile
function who retained function at 3 years was strikingly
similar between the group treated with predominantly IMRT
in the Barocas study and the group in the present study treated
with SBRT (56% vs 55%). Interestingly, despite younger age
(mean 62 years) and better baseline sexual HRQoL (mean
score 65), the erectile function preservation in those treated
with nerve-sparing RP was 46%, approximately 10 percentage
points lower than either radiation treatment method.
Prospective comparisons are needed to confirm these findings.
The PACE trial, a phase III study, will directly compare
methods by randomizing operable patients to SBRT or RP, and
non-operable candidates to SBRT or EBRT [12]. Our findings
lend reassurance and support for the ongoing PACE trial
whose results will potentially be able to validate our model as
they are collecting similar EPIC-26 data. An additional trial
comparing moderate hypofractionation with SBRT is in process
through the NRG Oncology cooperative group.
Several additional limitations of this study are worth discussion.
No single assessment is likely to capture post-treatment sexual
function both clearly and comprehensively. Beyond the
validated EPIC-26 inventory, we also reported results from the
commonly utilized IIEF-5 (SHIM) inventory with similar
results using a threshold of ≥16. Further validation of our model
should be pursued given the patients were treated at a single
institution. In addition, only the penile bulb was identified as an
avoidance structure in the present study. Radiation injury and
erectile function is known to be complex [28], and vessel-
sparing techniques have been shown to provide promising
results [29], but no effort was made to spare these structures in
the present study. Further, while the present study included
baseline sexual aid utilization, the impact of continued or new
sexual aid use on erectile function was limited given the nature
of EPIC-26. Finally, unlike conventionally fractionated EBRT,
where the benefit of ADT on clinically meaningful outcomes
has been established in multiple phase III trials [30,31], the
benefit of ADT in patients treated with SBRT is uncertain as no
randomized controlled trials have been performed to date.
Given the associated decline in sexual function with ADT
administration, further studies should be pursued to understand
the added clinical benefit of hormonal therapy in this setting.
In conclusion, long-term erectile function in men treated with
prostate SBRT is promising. We provide a practical, clinically
relevant model to estimate the probability of functional
erections to help guide physician- and patient-shared
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decision-making. Pretreatment age, baseline sexual domain
HRQoL and BMI are powerful predictors of long-term
erectile function.
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